#glp1ras — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #glp1ras, aggregated by home.social.
-
https://www.europesays.com/es/563606/ Un medicamento experimental produce una pérdida de peso drástica #BariatricSurgery #Business #ClinicalTrials #Drugs(Pharmaceuticals) #Economía #Economy #EliLillyAndCompany #ES #España #GLP1RAs(Drug) #Hormones #obesity #Spain #SurgeryAndSurgeons #UnitedStates #weight
-
https://www.europesays.com/news/31329/ Experimental Drug Yields Dramatic Weight Loss #BariatricSurgery #ClinicalTrials #Drugs(Pharmaceuticals) #EliLillyAndCompany #GLP1RAs(Drug) #Headlines #Hormones #News #Obesity #SurgeryAndSurgeons #TopStories #UnitedStates #Weight
-
https://www.europesays.com/uk/972773/ How Has Your Shopping Changed in the Era of Weight-Loss Drugs? #Drugs(Pharmaceuticals) #GLP1RAs(Drug) #Health #Medication #Ozempic(Drug) #ShoppingAndRetail #UK #UnitedKingdom #weight
-
https://www.europesays.com/ie/453971/ 6 Common Medications That May Decrease Dementia Risk #Alzheimer'sDisease #BloodPressure #Brain #Cholesterol #ClinicalTrials #ContentType:Service #dementia #diabetes #Diphtheria #Drugs(Pharmaceuticals) #Éire #GLP1RAs(Drug) #Health #Ibuprofen(Drug) #IE #ImmuneSystem #Influenza #Ireland #Lithium(Drug) #Medication #memory #Research #Shingles(Disease) #Tetanus #VaccinationAndImmunization
-
Use of GLP-1 RAs is associated with a 2-fold higher risk of Macular Degeneration
https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2834964
#HackerNews #GLP1RAs #MacularDegeneration #HealthRisk #Ophthalmology #JAMA
-
Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes: https://www.acpjournals.org/doi/10.7326/M23-2718 “#Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid #T2DM and #TUD compared with other antidiabetes medications including other #GLP1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide’s potential for TUD treatment.”
-
Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes: https://www.acpjournals.org/doi/10.7326/M23-2718 “#Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid #T2DM and #TUD compared with other antidiabetes medications including other #GLP1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide’s potential for TUD treatment.”
-
Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes: https://www.acpjournals.org/doi/10.7326/M23-2718 “#Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid #T2DM and #TUD compared with other antidiabetes medications including other #GLP1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide’s potential for TUD treatment.”
-
Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes: https://www.acpjournals.org/doi/10.7326/M23-2718 “#Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid #T2DM and #TUD compared with other antidiabetes medications including other #GLP1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide’s potential for TUD treatment.”
-
Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes: https://www.acpjournals.org/doi/10.7326/M23-2718 “#Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid #T2DM and #TUD compared with other antidiabetes medications including other #GLP1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide’s potential for TUD treatment.”